Novartis announced the construction of a new 46,000‑square‑foot radioligand therapy (RLT) manufacturing facility in Denton, Texas, marking the company’s fifth RLT site nationwide and its first in the state.
The new plant is part of a $23 billion U.S. investment plan that aims to bring all key Novartis medicines onshore, improve supply‑chain resilience, and support the launch of future RLT products such as Pluvicto and Lutathera.
The expansion is driven by a sharp rise in demand for RLTs, which are increasingly used in earlier treatment lines and for additional tumor types. The new site will help Novartis meet this demand while maintaining the speed and precision required for time‑sensitive radiopharmaceuticals.
Construction is slated to begin in 2026, with the facility expected to be fully operational in 2028. The Denton plant will add significant capacity to the company’s U.S. network, which already includes sites in New Jersey, Indiana, California, and Florida.
CEO Vas Narasimhan said, “RLT has the potential to revolutionize cancer care. The addition of our fifth RLT manufacturing site in the US strengthens our ability to meet growing demand, building the capabilities needed to deliver these next‑generation treatments with the speed and precision they require.”
The investment is expected to create jobs in bioengineering, advanced manufacturing, quality, and operations, reinforcing Texas’s reputation as a biotech hub and supporting the broader goal of 100 % domestic production of Novartis’ key medicines.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.